Hepatology International

, Volume 13, Issue 6, pp 688–694 | Cite as

Hepatocellular carcinoma and non-alcoholic fatty liver disease

  • Pegah Golabi
  • Logan Rhea
  • Linda Henry
  • Zobair M. YounossiEmail author
Review Article


Nonalcoholic fatty liver disease (NAFLD) is considered the most common liver disorder worldwide, affecting 25.2% of the general population. In fact, NAFLD is among the most common etiologies for hepatocellular carcinoma (HCC). The burden of NAFLD is primarily driven by the epidemic of obesity and type 2 diabetes which are expected to worsen throughout the world. In this context, the burden of NAFLD and associated HCC and cirrhosis are also expected to increase. Despite its growing disease burden, diagnostic tools and treatment modalities remain very limited. This conundrum of increasing prevalence and limited treatment options will be reflected as increasing number of NAFLD-related cirrhosis and HCC cases. This article reviews the most updated information about NAFLD-related HCC and provides some insight into strategies that must be considered to reduce its potential disease burden.


Non-alcoholic fatty liver disease Non-alcoholic steatohepatitis Cirrhosis Hepatocellular carcinoma Hepatitis C virus Hepatitis B virus 



Diabetes mellitus


Hepatitis B virus


Hepatocellular carcinoma


Hepatitis C virus


Non-alcoholic fatty liver disease


Non-alcoholic steatohepatitis


Patatin-like phospholipase domain containing 3


Single-nucleotide polymorphisms


Transmembrane 6 superfamily member 2




Compliance with ethical standards

Conflict of interest

Zobair M. Younossi has received research funds or served as consultant to Gilead Sciences, Intercept, NovoNordisk, BMS, Abbvie, BMS, Terns and Viking. Pegah Golabi, Logan Rhea and Linda Henry have no conflict of interest to disclose.


  1. 1.
    Younossi ZM, Loomba R, Anstee QM, Rinella ME, Bugianesi E, Marchesini G, et al. Diagnostic modalities for non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH) and associated fibrosis. Hepatology. 2017. CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018;67:328–357. CrossRefPubMedGoogle Scholar
  3. 3.
    Golabi P, Otgonsuren M, de Avila L, Sayiner M, Rafiq N, Younossi ZM. Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD). Medicine 2018;97:e0214. CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Younossi ZM, Stepanova M, Rafiq N, Makhlouf H, Younoszai Z, Agrawal R, et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology 2011;53:1874–1882. CrossRefPubMedGoogle Scholar
  5. 5.
    Younossi ZM, Stepanova M, Rafiq N, Henry L, Loomba R, Makhlouf H, et al. Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease. Hepatol Commun 2017;1:421–428. CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Younossi Z, Stepanova M, Sanyal AJ, Harrison SA, Ratziu V, Abdelmalek MF, et al. The conundrum of cryptogenic cirrhosis: adverse outcomes without treatment options. J Hepatol 2018;69:1365–1370. CrossRefPubMedGoogle Scholar
  7. 7.
    Paradis V, Zalinski S, Chelbi E, Guedj N, Degos F, Vilgrain V, et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 2009;49:851–859. CrossRefPubMedGoogle Scholar
  8. 8.
    Golabi P, Sayiner M, Fazel Y, Koenig A, Henry L, Younossi ZM. Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis. Expert Rev Gastroenterol Hepatol 2016;10:63–71. CrossRefPubMedGoogle Scholar
  9. 9.
    Younossi Z, Henry L. Contribution of alcoholic and nonalcoholic fatty liver disease to the burden of liver-related morbidity and mortality. Gastroenterology 2016;150:1778–1785. CrossRefGoogle Scholar
  10. 10.
    Kim D, Li AA, Perumpail BJ, Gadiparthi C, Kim W, Cholankeril G, et al. Changing trends in etiology-based and ethnicity-based annual mortality rates of cirrhosis and hepatocellular carcinoma in the United States. Hepatology 2019. CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Petrick JL, Kelly SP, Altekruse SF, McGlynn KA, Rosenberg PS. Future of hepatocellular carcinoma incidence in the United States forecast through 2030. J Clin Oncol 2016;34:1787–1794. CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Altekruse SF, Devesa SS, Dickie LA, McGlynn KA, Kleiner DE. Histological classification of liver and intrahepatic bile duct cancers in SEER registries. J Registry Manag 2011;38:201–205. Accessed 25 Oct 2019
  13. 13.
    Golabi P, Fazel S, Otgonsuren M, Sayiner M, Locklear CT, Younossi ZM. Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities. Medicine 2017;96:e5904. CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Sayiner M, Golabi P, Younossi ZM. Disease burden of hepatocellular carcinoma: a global perspective. Dig Dis Sci 2019. CrossRefPubMedGoogle Scholar
  15. 15.
    Sayiner M, Younossi ZM. Identifying patients at risk from nonalcoholic fatty liver-related hepatocellular carcinomas. Hepat Oncol 2016;3:101–103. CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Hester D, Golabi P, Paik J, Younossi I, Mishra A, Younossi ZM. Among medicare patients with hepatocellular carcinoma, non-alcoholic fatty liver disease is the most common etiology and cause of mortality. J Clin Gastroenterol 2019. CrossRefPubMedGoogle Scholar
  17. 17.
    Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol 2019;70:151–171. CrossRefPubMedGoogle Scholar
  18. 18.
    Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73–84. CrossRefPubMedGoogle Scholar
  19. 19.
    Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2018;15:11–20. CrossRefPubMedGoogle Scholar
  20. 20.
    Kim D, Touros A, Kim WR. Nonalcoholic fatty liver disease and metabolic syndrome. Clin Liver Dis 2018;22:133–140. CrossRefPubMedGoogle Scholar
  21. 21.
    Ogurtsova K, da Rocha-Fernandes JD, Huang Y, Linnenkamp U, Guariguata L, Cho NH, et al. IDF diabetes atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract 2017;128:40–50. CrossRefPubMedGoogle Scholar
  22. 22.
    Nanditha A, Ma RCW, Ramachandran A, Snehalatha C, Chan JCN, Chia KS, et al. Diabetes in Asia and the Pacific: implications for the global epidemic. Diabetes Care 2016;39:472–485. CrossRefPubMedGoogle Scholar
  23. 23.
    Unnikrishnan R, Pradeepa R, Joshi SR, Mohan V. Type 2 diabetes: demystifying the global epidemic. Diabetes 2017;66:1432–1442. CrossRefPubMedGoogle Scholar
  24. 24.
    Wong VWS, Chu WCW, Wong GLH, Chan RSM, Chim AML, Ong A, et al. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut 2012;61:409–415. CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Li J, Zou B, Yeo YH, Feng Y, Xie X, Lee DH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2019;4:389–398 CrossRefPubMedGoogle Scholar
  26. 26.
    Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology 2018;67:123–133. CrossRefPubMedGoogle Scholar
  27. 27.
    Alam S, Gupta UD, Alam M, Kabir J, Chowdhury ZR, Alam AKMK. Clinical, anthropometric, biochemical, and histological characteristics of nonobese nonalcoholic fatty liver disease patients of Bangladesh. Indian J Gastroenterol 2014;33:452–457. CrossRefPubMedGoogle Scholar
  28. 28.
    Lazo M, Hernaez R, Eberhardt MS, Bonekamp S, Kamel I, Guallar E, et al. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988–1994. Am J Epidemiol 2013;178:38–45. CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Hagström H, Nasr P, Ekstedt M, Hammar U, Stål P, Hultcrantz R, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol 2017;67:1265–1273. CrossRefPubMedGoogle Scholar
  30. 30.
    Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2015;149:389–397.e10. CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology 2017;65:1557–1565. CrossRefGoogle Scholar
  32. 32.
    Ekstedt M, Hagström H, Nasr P, Fredrikson M, Stål P, Kechagias S, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015;61:1547–1554. CrossRefPubMedGoogle Scholar
  33. 33.
    Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015;13:643–654.e1–9. e39–40) CrossRefPubMedGoogle Scholar
  34. 34.
    Alkhouri N, McCullough AJ. Noninvasive diagnosis of NASH and liver fibrosis within the spectrum of NAFLD. Gastroenterol Hepatol 2012;8:661–668. Accessed 25 Oct 2019
  35. 35.
    Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA 2015;313:2263–2273. CrossRefPubMedGoogle Scholar
  36. 36.
    Atay K, Canbakan B, Alan O, Koroglu E, Hatemi I, Kepil N et al. Evaluation of non-invasive diagnostic methods as indicators of fibrosis in patients with nonalcoholic fatty liver disease. Biomed Res 2017. Accessed 25 Oct 2019
  37. 37.
    Johnson PJ, Pirrie SJ, Cox TF, Berhane S, Teng M, Palmer D, et al. The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers. Cancer Epidemiol Biomarkers Prev 2014;23:144–153. CrossRefPubMedGoogle Scholar
  38. 38.
    Fabbrini E, Mohammed BS, Magkos F, Korenblat KM, Patterson BW, Klein S. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology 2008;134:424–431. CrossRefPubMedGoogle Scholar
  39. 39.
    Perla FM, Prelati M, Lavorato M, Visicchio D, Anania C. The role of lipid and lipoprotein metabolism in non-alcoholic fatty liver disease. Children 2017. CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Nassir F, Ibdah JA. Role of mitochondria in nonalcoholic fatty liver disease. Int J Mol Sci 2014;15:8713–42. CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 2016;65:1038–1048. CrossRefPubMedGoogle Scholar
  42. 42.
    Hodge DR, Hurt EM, Farrar WL. The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer 2005;41:2502–2512. CrossRefPubMedGoogle Scholar
  43. 43.
    Dongiovanni P, Romeo S, Valenti L. Hepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors. World J Gastroenterol 2014;20:12945–12955. CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Krawczyk M, Stokes CS, Romeo S, Lammert F. HCC and liver disease risks in homozygous PNPLA3 p.I148M carriers approach monogenic inheritance. J Hepatol 2015. CrossRefPubMedGoogle Scholar
  45. 45.
    Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol 2013. CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Bray F, Ferlay J, Laversanne M, Brewster DH, Gombe Mbalawa C, Kohler B, et al. Cancer incidence in five continents: inclusion criteria, highlights from volume X and the global status of cancer registration. Int J Cancer 2015;137:2060–2071. CrossRefPubMedGoogle Scholar
  47. 47.
    El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365:1118–1127. CrossRefPubMedGoogle Scholar
  48. 48.
    Singal AG, Manjunath H, Yopp AC, Beg MS, Marrero JA, Gopal P, et al. The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis. Am J Gastroenterol 2014;109:325–334. CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Younossi ZM, Otgonsuren M, Henry L, Venkatesan C, Mishra A, Erario M, et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology 2015;62:1723–1730. CrossRefPubMedGoogle Scholar
  50. 50.
    Piscaglia F, Svegliati-Baroni G, Barchetti A, Pecorelli A, Marinelli S, Tiribelli C, et al. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study. Hepatology 2016;63:827–838. CrossRefPubMedGoogle Scholar
  51. 51.
    Giannini EG, Marabotto E, Savarino V, Trevisani F, di Nolfo MA, Del Poggio P, et al. Hepatocellular carcinoma in patients with cryptogenic cirrhosis. Clin Gastroenterol Hepatol 2009;7:580–585. CrossRefPubMedGoogle Scholar
  52. 52.
    Younossi Z, Stepanova M, Ong JP, Jacobson IM, Bugianesi E, Duseja A, et al. nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol 2018. CrossRefPubMedGoogle Scholar
  53. 53.
    Mittal S, El-Serag HB, Sada YH, Kanwal F, Duan Z, Temple S, et al. Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2016;14:124–131.e1. CrossRefPubMedGoogle Scholar
  54. 54.
    Chen YC, Sheen IS, Chu CM, Liaw YF. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology 2002;123:1084–1089. CrossRefPubMedGoogle Scholar
  55. 55.
    Chu CM, Lin DY, Liaw YF. Clinical and virological characteristics post HBsAg seroclearance in hepatitis B virus carriers with hepatic steatosis versus those without. Dig Dis Sci 2013;58:275–281. CrossRefPubMedGoogle Scholar
  56. 56.
    Seto WK. Chronic hepatitis B and metabolic risk factors: a call for rigorous longitudinal studies. World J Gastroenterol 2019;25:282–286. CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Yilmaz B, Koklu S, Buyukbayram H, Yalçin K, Korkmaz U, Posul E, et al. Chronic hepatitis B associated with hepatic steatosis, insulin resistance, necroinflammation and fibrosis. Afr Health Sci 2015;15:714–718. CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Charatcharoenwitthaya P, Pongpaibul A, Kaosombatwattana U, Bhanthumkomol P, Bandidniyamanon W, Pausawasdi N, et al. The prevalence of steatohepatitis in chronic hepatitis B patients and its impact on disease severity and treatment response. Liver Int 2017;37:542–551 Scholar
  59. 59.
    Wang CC, Kao JH. Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: a cohort study. Hepatology 2017. CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Adami HO, Chow WH, Nyrén O, Berne C, Linet MS, Ekbom A, et al. Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst 1996;88:1472–1477. CrossRefPubMedGoogle Scholar
  61. 61.
    Nair S, Mason A, Eason J, Loss G, Perrillo RP. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? Hepatology 2002;36:150–155. CrossRefPubMedGoogle Scholar
  62. 62.
    Lagiou P, Kuper H, Stuver SO, Tzonou A, Trichopoulos D, Adami HO. Role of diabetes mellitus in the etiology of hepatocellular carcinoma. J Natl Cancer Inst 2000;92:1096–1099. CrossRefPubMedGoogle Scholar
  63. 63.
    Yasui K, Hashimoto E, Komorizono Y, Koike K, Arii S, Imai Y, et al. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol 2011;9:428–433 e50) CrossRefPubMedGoogle Scholar
  64. 64.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69–90. CrossRefPubMedGoogle Scholar
  65. 65.
    Anstee QM, Day CP. The genetics of nonalcoholic fatty liver disease: spotlight on PNPLA3 and TM6SF2. Semin Liver Dis 2015;35:270–290. CrossRefPubMedGoogle Scholar
  66. 66.
    Liu Y-L, Reeves HL, Burt AD, Tiniakos D, McPherson S, Leathart JBS, et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat Commun 2014;5:4309. CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M. From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol 2019. CrossRefPubMedGoogle Scholar
  68. 68.
    Than NN, Ghazanfar A, Hodson J, Tehami N, Coldham C, Mergental H, et al. Comparing clinical presentations, treatments and outcomes of hepatocellular carcinoma due to hepatitis C and non-alcoholic fatty liver disease. QJM 2017;110:73–81. CrossRefPubMedGoogle Scholar
  69. 69.
    European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908–943. CrossRefGoogle Scholar
  70. 70.
    Reig M, Gambato M, Man NK, Roberts JP, Victor D, Orci LA, et al. Should patients With NAFLD/NASH Be surveyed for HCC? Transplantation 2019;103:39–44. CrossRefPubMedGoogle Scholar
  71. 71.
    Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the US. Hepatology 2014;59:2188–2195. CrossRefPubMedGoogle Scholar
  72. 72.
    Chen H-P, Shieh J-J, Chang C-C, Chen T-T, Lin J-T, Wu M-S, et al. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut 2013;62:606–615. CrossRefPubMedGoogle Scholar
  73. 73.
    Zhang H, Gao C, Fang L, Zhao H-C, Yao S-K. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysis. Scand J Gastroenterol 2013;48:78–87. CrossRefPubMedGoogle Scholar
  74. 74.
    Yan J, Yao B, Kuang H, Yang X, Huang Q, Hong T, et al. Liraglutide, sitagliptin, and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Hepatology 2019;69:2414–2426. CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Marengo A, Rosso C, Bugianesi E. Liver cancer: connections with obesity, fatty liver, and cirrhosis. Annu Rev Med 2016;67:103–117. CrossRefPubMedGoogle Scholar
  76. 76.
    Singh S, Singh PP, Singh AG, Murad MH, Sanchez W. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology 2013;144:323–332. CrossRefPubMedGoogle Scholar

Copyright information

© Asian Pacific Association for the Study of the Liver 2019

Authors and Affiliations

  • Pegah Golabi
    • 1
    • 2
  • Logan Rhea
    • 1
  • Linda Henry
    • 2
  • Zobair M. Younossi
    • 1
    • 2
    Email author
  1. 1.Center For Liver Disease, Department of MedicineInova Fairfax Medical CampusFalls ChurchUSA
  2. 2.Betty and Guy Beatty Center for Integrated ResearchInova Health System, Claude Moore Health Education and Research BuildingFalls ChurchUSA

Personalised recommendations